Featured Articles

  1. Nasdaq's New MVLS Rule: Rethinking Exchange Choice For Micro-Caps 8/21/2026

    Nasdaq’s new $5 million MVLS rule raises delisting risk for micro-cap life sciences companies, making exchange choice an ongoing board governance issue.

  2. What Biotech Leaders Can Learn From The Cockpit 8/18/2026

    Patrick Mooney, CEO of SpyGlass Pharma, shares how insights from the cockpit have shaped his approach to leading an innovative biotech.

  3. M&A In The Life Sciences Sector: Challenges And Opportunities 8/14/2026

    Life Sciences M&A policies in the EU, Israel, and Singapore are shifting, creating new opportunities for drug developers, according to legal experts at Meritas.

  4. Biotech Playbook Breakdown: Who Will Risk Developing Tomorrow's Cures? 8/11/2026

    Biotech’s old risk-sharing model is breaking down, forcing academia, investors, pharma, and healthcare systems to collaborate earlier to bring cures to patients.

  5. July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing 8/7/2026

    Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.

  6. Big Pharma Can't Merge Its Way Out Of An Innovation Problem 8/6/2026

    Mega-mergers may cut costs, but they won’t fix pharma’s innovation gap. Breakthroughs come through biotech partnerships, writes Sofinnova’s Jim Healy, M.D., Ph.D.

  7. Why Life Sciences Demand Venture Formation Over Venture Capital 8/3/2026

    The life sciences industry needs venture formation, not traditional VC, to turn academic breakthroughs into successful startups, writes William Garner, M.D.

  8. When AI Changes A Deal: Rethinking Risk, Milestones, And Timing In Life Sciences M&A 7/29/2026

    AI is shifting life sciences M&A risk from early milestones to later validation, reshaping valuation, diligence, and deal timing, according to experts at Sidley. 

  9. Bridging The Gap: The Contract-To-Ledger Divide In Life Sciences 7/23/2026

    Contract wording in life sciences deals can materially affect revenue recognition, metrics, and disclosures, making early legal-accounting review essential.

  10. Rebuilding the Innovation Engine: How We Got Here And What Comes Next 7/20/2026

    Federal investment in basic science built America’s innovation engine, but declining support is threatening U.S. leadership, writes Dietrich Stephan, Ph.D.